Aluminio en pacientes con terapia de reemplazo renal crónico con hemodiálisis en dos unidades renales en Bogotá

Cárdenas, Omayda; Segura, Omar; Puentes, William; Sanabria, Mauricio; Nava, Gabriel Miranda; Torrenegra, Rubén

doi:10.1590/s0124-00642010000400013

Cited by 2 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Except in rare cases of equipment failure (CDC 2008) or inadvertent introduction of Al into dialysate (Berend et al 2001), elevated serum Al and risk of dialysis encephalopathy have for all practical purposes been eliminated by controlling Al concentrations in dialysate to less than 10 μg/L (ANSI/AAMI 2004, CAN/CSA-ISO 2011) and substituting Al phosphate binders with Ca acetate, Ca carbonate, sevelamer, or lanthanum. Abnormally high plasma and serum Al levels can result after daily consumption of the customary approximately 4 g of Al-based phosphate chelators even with regular clinical monitoring (Arenas et al 2008, Cárdenas et al 2010, Gault et al 2006). Those observations contrast with Jimenez et al (2011) and Mudge et al (2011) who concluded Al-based phosphate chelators are not only economical and effective, but they have a high rate of patient compliance without undue health risk.…”

Section: Environmental and Occupational Exposurementioning

confidence: 99%

“…Cárdenas and associates (2010) compared serum Al in 63 patients on renal dialysis (21–89 years of age) with that of 20 healthy referents (24–73 years of age). The dialysis water had less than 2 μg Al/L and the mean serum Al in healthy people (8.05 ± 4.3 μg/L) was less than the serum Al in those with kidney disease (26.5 ± 8.0 μg/L).…”

Section: Environmental and Occupational Exposurementioning

confidence: 99%

“…The dialysis water had less than 2 μg Al/L and the mean serum Al in healthy people (8.05 ± 4.3 μg/L) was less than the serum Al in those with kidney disease (26.5 ± 8.0 μg/L). Given the very low Al concentration in dialysis water, Cárdenas et al (2010) concluded that consumption of Al(OH) 3 to mitigate hyperphosphatemia was the primary source of elevated serum Al.…”

Section: Environmental and Occupational Exposurementioning

confidence: 99%

See 2 more Smart Citations

Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts

Willhite¹,

Karyakina²,

Yokel³

et al. 2014

Critical Reviews in Toxicology

333

201

View full text Add to dashboard Cite

Aluminum (Al) is a ubiquitous substance encountered both naturally (as the third most abundant element) and intentionally (used in water, foods, pharmaceuticals, and vaccines); it is also present in ambient and occupational airborne particulates. Existing data underscore the importance of Al physical and chemical forms in relation to its uptake, accumulation, and systemic bioavailability.Address for correspondence: Calvin C. Willhite, Risk Sciences International, 55 Metcalfe Street, Suite 700, Ottawa, ON, Canada. calvinwillhite@hotmail.com. Declaration of interestPartial funding for this work was provided by a contract to review the recent scientific literature on health effects of aluminum between the International Aluminium Institute (IAI, www.world-aluminium.org), the Aluminium Reach Consortium (ARC, www.aluminium-reach-consortium.eu), and Risk Sciences International (RSI, www.risksciences.com), a Canadian company established in 2006 in partnership with the University of Ottawa. Additional financial support was provided by the Natural Sciences and Engineering Research Council of Canada (NSERC) to D. Krewski, who holds the NSERC Chair in Risk Science at the University of Ottawa. C.C. Willhite, N.A. Karyakina, F. Momoli, and N. Yenugadhati were compensated by RSI for their contributions to the review. I. Arnold, T. Wisniewski and R. Yokel received no compensation from RSI for their contributions to this work. The authors, whose affiliations are shown on the title page, had sole responsibility for preparation of this paper, including determining the strategy for reviewing the scientific literature summarized in this article, synthesizing the findings, and drawing conclusions. Scientists associated with IAI/ARC were given the opportunity to review and offer technical comments on the paper, prior to submission to Critical Reviews in Toxicology. I. Arnold serves as a consultant to the International Aluminium Institute. None of the authors have appeared before regulatory agencies on behalf of the sponsors, or appeared as experts in legal proceedings concerning matters reviewed in this paper. The scientific opinions and conclusions expressed in the paper are exclusively those of the authors, and are independent of the sources of financial support. HHS Public Access Author Manuscript Author ManuscriptAuthor Manuscript Author ManuscriptThe present review represents a systematic examination of the peer-reviewed literature on the adverse health effects of Al materials published since a previous critical evaluation compiled by Krewski et al. (2007). The scientific literature on the adverse health effects of Al is extensive. Health risk assessments for Al must take into account individual co-factors (e.g., age, renal function, diet, gastric pH). Conclusions from the current review point to the need for refinement of the PTWI, reduction of Al contamination in PN solutions, justification for routine addition of Al to vaccines, and harmonization of OELs for Al substances.

show abstract

Section: Environmental and Occupational Exposurementioning

confidence: 99%

Section: Environmental and Occupational Exposurementioning

confidence: 99%

Section: Environmental and Occupational Exposurementioning

confidence: 99%

See 1 more Smart Citation

Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts

Willhite¹,

Karyakina²,

Yokel³

et al. 2014

Critical Reviews in Toxicology

333

201

View full text Add to dashboard Cite

show abstract

Blood Aluminum Levels in Patients with Hemodialysis and Peritoneal Dialysis

Chuang

Tsai

Wang

et al. 2022

IJERPH

View full text Add to dashboard Cite

Background. This retrospective observational study attempted to examine the prevalence of abnormal blood aluminum levels in dialysis patients, and to explore the association of pathogenic factors, such as demographic, clinical, laboratory as well as the use of phosphate binding drugs, drugs for secondary hyperparathyroidism and erythropoiesis-stimulating drugs with the blood aluminum levels. Methods. The study included 1175 patients (874 hemodialysis and 301 peritoneal dialysis), recruited from Chang Gung Memorial Hospital in November 2020. Patients were stratified into two groups by their blood aluminum levels, as normal (<2 µg/dL, n = 1150) or abnormal (≥2 µg/dL, n = 25). Results. The patients aged 60.4 ± 13.2 years and were dialyzed for 8.6 ± 8.1 years. The average blood aluminum level was 1.0 ± 0.4 µg/dL. Patients with abnormal blood aluminum levels received more sevelamer than patients with normal blood aluminum level (p = 0.014). Patients with abnormal blood aluminum levels had higher platelet count (p = 0.001), triglyceride (p < 0.001) and total iron binding capacity (p = 0.003) than patients with normal blood aluminum levels. Moreover, the cardiothoracic ratio was higher in patients with abnormal blood aluminum levels than patients with normal blood aluminum levels (p = 0.003). Conclusions. The prevalence of abnormal blood aluminum levels was low at 2.2%. Nevertheless, the linking of cardiothoracic ratio of more than 0.5 as well as elevated blood platelet count and triglyceride level with blood aluminum levels are interesting, and warranted more researches in this area.

show abstract

Aluminio en pacientes con terapia de reemplazo renal crónico con hemodiálisis en dos unidades renales en Bogotá

Cited by 2 publications

References 16 publications

Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts

Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts

Blood Aluminum Levels in Patients with Hemodialysis and Peritoneal Dialysis

Contact Info

Product

Resources

About